-$1.15 Earnings Per Share Expected for Spero Therapeutics Inc (NASDAQ:SPRO) This Quarter

Analysts expect that Spero Therapeutics Inc (NASDAQ:SPRO) will announce earnings of ($1.15) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($1.37) and the highest is ($0.95). Spero Therapeutics reported earnings per share of ($0.74) during the same quarter last year, which indicates a negative year over year growth rate of 55.4%. The company is expected to report its next quarterly earnings results on Thursday, August 13th.

According to Zacks, analysts expect that Spero Therapeutics will report full-year earnings of ($4.09) per share for the current year, with EPS estimates ranging from ($4.69) to ($3.71). For the next fiscal year, analysts anticipate that the company will post earnings of ($3.67) per share, with EPS estimates ranging from ($4.76) to ($2.91). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.22) earnings per share for the quarter, topping the consensus estimate of ($1.35) by $0.13. The business had revenue of $1.70 million during the quarter, compared to the consensus estimate of $3.36 million. Spero Therapeutics had a negative net margin of 654.03% and a negative return on equity of 88.22%.

Several analysts have weighed in on the stock. Stifel Nicolaus lowered their price target on shares of Spero Therapeutics from $22.00 to $21.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. ValuEngine raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 28th. HC Wainwright upped their price objective on shares of Spero Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research note on Tuesday, March 17th. Finally, Oppenheimer started coverage on shares of Spero Therapeutics in a research note on Friday, May 8th. They set a “buy” rating and a $20.00 price objective for the company. Eight analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $20.50.

Spero Therapeutics stock traded up $0.54 during mid-day trading on Friday, hitting $12.50. The company’s stock had a trading volume of 221,761 shares, compared to its average volume of 240,055. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.31 and a current ratio of 4.31. The business has a 50 day moving average price of $9.82 and a 200-day moving average price of $9.69. Spero Therapeutics has a 12 month low of $5.25 and a 12 month high of $14.38.

A number of hedge funds have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC raised its stake in Spero Therapeutics by 7.4% in the first quarter. Janney Montgomery Scott LLC now owns 14,500 shares of the company’s stock worth $117,000 after buying an additional 1,000 shares in the last quarter. Rhumbline Advisers raised its stake in Spero Therapeutics by 6.7% in the first quarter. Rhumbline Advisers now owns 16,417 shares of the company’s stock worth $133,000 after buying an additional 1,030 shares in the last quarter. BNP Paribas Arbitrage SA raised its stake in Spero Therapeutics by 37.3% in the first quarter. BNP Paribas Arbitrage SA now owns 3,834 shares of the company’s stock worth $31,000 after buying an additional 1,042 shares in the last quarter. Citigroup Inc. raised its stake in Spero Therapeutics by 68.6% in the first quarter. Citigroup Inc. now owns 4,042 shares of the company’s stock worth $33,000 after buying an additional 1,644 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in Spero Therapeutics by 11.4% in the first quarter. New York State Common Retirement Fund now owns 18,429 shares of the company’s stock worth $149,000 after buying an additional 1,879 shares in the last quarter. 48.09% of the stock is owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease.

Recommended Story: Determine Your Level of Risk Tolerance

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.